Proteocyte Diagnostics hosted their first global Straticyte meeting at the 6th World Oral Cancer Congress of the International Academy of Oral Oncology (IAOO) in India  on May 18, 2017. The meeting included leading oral cancer healthcare professionals from around the world.

Feedback from the attendees was very positive and Meeting Chair Dr. Jatin Shah, Memorial Sloan Kettering, New York, offered the perspective that “Straticyte offers a new avenue in predicting the risk of oral cancer.”

“Straticyte is very exciting technology.” said Dr. Terry Day, Professor and Director, Head and Neck Tumor Center, Medical University of South Carolina. Dr. Day hopes to begin evaluating Straticyte with patients in the summer of 2017.

Proteocyte Diagnostics’ first product Straticyte™ is a test that accurately predicts a patient’s risk of developing oral cancer.  Straticyte enables healthcare professionals to customize patient treatment, improving outcomes for patients at risk for developing cancer, while reassuring those patients who have minimal to no risk of disease progression. Straticyte is being offered on a complimentary basis until September 30, 2017.

The healthcare professionals attending the Straticyte meeting included representatives from MD Anderson, New York University, University of South Carolina, University of Chicago,  University of Toronto along with Germany, Australia and India.

“This was an opportunity to meet with key global opinion leaders and share the Straticyte science, gather relevant feedback and validate our plans for the rollout,” said John Davis, President and CEO of Proteocyte Diagnostics.

It is widely accepted that late diagnosis of oral cancer leads to one person in North America dying every hour from oral cancer and only a 50% survival rate. Those who do survive often must cope with disfigurement, pain and the inability to talk or eat normally.

“We can do better for patients. Straticyte is an advancement in technology and works with the current standard histopathology.  We believe this combination can make a real difference in patient outcomes for oral cancer,” said Davis.  “It’s critical that all key healthcare professionals in the oral cancer diagnosis and treatment pathway are made aware of Straticyte and have an opportunity to learn more and gain experience with the test.”

Proteocyte Diagnostics also exhibited and presented abstracts at the American Academy of Oral and Maxillofacial Pathology (AAOMP) Annual Meeting April 2017 and The American College of Oral and Maxillofacial Surgeons (ACOMS) and the Canadian Association of Oral and Maxillofacial Surgeons (CAOMS) Joint Scientific Conference and Exhibition in May 2017.

“Oral Maxillofacial and ENT Surgeons, along with Oral Pathologists, have confirmed a gap in diagnosis and are searching for something that will improve their patient’s outcomes. These healthcare professionals are front line with patients so they see the devastation that happens with a late diagnosis of oral cancer. They want and need new technology that predicts a patient’s progression to oral cancer,” said Dr. David Mock, former Dean of Dentistry at the University of Toronto.

Proteocyte Diagnostics will be continuing to reach out to healthcare professionals by exhibiting at the ADHA, AAOMS and the CDHA later this year.

“Face to face meetings with these healthcare professionals are critical to adoption of new technology like Straticyte. You need to be at key conferences to ensure your healthcare professional audience has an opportunity to ask critical questions and validate your approach,” said Davis.
About Proteocyte Diagnostics https://proteocyte.com

Proteocyte Diagnostics is a Canadian company designing tests that accurately predict your risk of developing cancer.  Their first product Straticyte™  is a novel prognostic oral precancer laboratory service that accurately predicts a patient’s risk of developing oral cancer. Straticyte objectively and accurately detects oral lesions at high risk of transforming to cancer and those that pose low risk. Early diagnosis of high risk lesions permits more effective and less traumatizing treatments. By identifying and treating oral cancer before it happens, clinicians can save lives, healthcare costs are reduced and quality of life of patients is improved. Identifying more accurately low risk precancerous lesions avoids unnecessary surgeries and allows clinicians to monitor patients regularly for peace of mind.